Spirulina and Glycogen Phosphorylase: Allosteric Glucose Mobilisation and AMPK Cross-Talk

Glycogen Phosphorylase Isoforms: PYGM, PYGL, and PYGB

Three tissue-specific isoforms of glycogen phosphorylase (GP) exist in mammals: PYGM (muscle), PYGL (liver), and PYGB (brain). All three catalyse the phosphorolytic cleavage of glucose from the non-reducing ends of glycogen chains, producing glucose-1-phosphate (G1P) rather than free glucose — a thermodynamically and logistically important distinction since G1P is immediately channelled into glycolysis via phosphoglucomutase (to glucose-6-phosphate, G6P) without consuming an ATP. Each isoform exists as a homodimer in its active state. PYGM is the dominant isoform in skeletal and cardiac muscle, where rapid glycogenolysis fuels contractile work. PYGL is the hepatic isoform; hepatic glycogenolysis contributes critically to fasting blood-glucose maintenance, particularly during the first 8–12 hours after a meal. PYGB is expressed in fetal and neonatal tissues and in adult brain, where it supports astrocyte glycogen — a reserve that sustains neuronal glucose supply during hypoglycaemic stress. All three isoforms share the same basic regulatory architecture but differ in allosteric sensitivity, particularly their response to AMP and glucose.

The b-to-a Interconversion: Phosphorylase Kinase and PKA

Glycogen phosphorylase exists in two covalent forms distinguished by the phosphorylation state of Ser14 (in the N-terminal regulatory tail). Phosphorylase b (dephosphorylated) is the resting form and is substantially less active except when AMP concentrations are high. Phosphorylase a (Ser14 phosphorylated) is active even in the absence of AMP. The conversion of b to a is catalysed by phosphorylase kinase (PhK; a hexadecameric complex with subunit composition (αβγδ)₄). PhK is itself regulated by two independent signals: (1) PKA-dependent phosphorylation of PhK α and β subunits (Ser1018 and Ser700 respectively), activated downstream of glucagon (hepatic) or epinephrine (β-adrenergic) signalling through cAMP; (2) Ca²⁺/calmodulin binding to the intrinsic δ subunit of PhK (which is calmodulin itself), enabling muscle glycogenolysis to be triggered directly by the same Ca²⁺ transient that initiates contraction. The combined PKA + Ca²⁺ activation of PhK during fight-or-flight ensures that both hormonal (systemic) and mechanical (local) signals converge on rapid glycogenolysis. Phosphorylase a is returned to b by protein phosphatase 1 (PP1), which is itself regulated by glycogen-targeting subunits (GL in liver, GM in muscle) and inhibited by phospho-inhibitor-1 and phospho-DARPP-32 downstream of PKA.

Allosteric Regulation: AMP, ATP, G6P, and Glucose

The allosteric regulation of phosphorylase b is one of the paradigm cases in enzyme biochemistry. At the allosteric site (distinct from the active site and the Ser14 phosphorylation site), AMP acts as a potent activator of phosphorylase b, shifting it toward the active R-state conformation by promoting the T-to-R quaternary transition. ATP and G6P are competitive inhibitors at the same allosteric site, displacing AMP and favouring the T-state. This creates a direct metabolic sensor: when the AMP:ATP ratio rises (during exercise or ischaemia), phosphorylase b is allosterically activated without requiring covalent modification, providing rapid glycogenolysis within the first seconds of high-intensity work before hormonal signals arrive. Glucose itself is an allosteric inhibitor of phosphorylase a specifically (PYGL>PYGM); glucose binding to the active site of hepatic GP-a promotes its dephosphorylation by PP1, creating a glucose-mediated feedback that switches off hepatic glycogenolysis when portal glucose rises. This is the molecular basis for the observation that glucose infusion acutely suppresses hepatic glycogen breakdown even in the hyperglucagonaemic state. G6P inhibits GP-b and is the primary brake on muscle glycogenolysis when glycolytic flux generates G6P faster than it can be consumed downstream.

Glycogen Debranching Enzyme and the Structural Constraint on Phosphorylase

Glycogen phosphorylase can only cleave α(1→4) glycosidic bonds and cannot proceed past four glucose residues from an α(1→6) branch point. Complete glycogenolysis therefore requires the glycogen debranching enzyme (GDE; AGL — amylo-α-1,6-glucosidase/4-α- glucanotransferase), which performs two sequential reactions: the glucan-transferase activity transfers a trisaccharide from the branch stub to the end of an adjacent chain (regenerating a linear substrate for phosphorylase), and the glucosidase activity hydrolyses the single α(1→6)-linked glucose residue remaining at the branch point, releasing free glucose (not G1P). This means approximately 8–10% of glycogen-derived glucose emerges as free glucose rather than G1P, and this fraction bypasses glycolysis entry (since free glucose must be phosphorylated by hexokinase/glucokinase). Mutations in AGL cause glycogen storage disease type III (Cori disease), characterised by accumulation of limit-dextrin (debranching-incompetent glycogen), hepatomegaly, and hypoglycaemia.

GSK3 and Glycogen Synthase: The Synthetic Counterpart

Glycogen metabolism is bidirectional and the synthetic arm is controlled by glycogen synthase (GYS1 in muscle, GYS2 in liver), which is inhibited by phosphorylation at multiple N- and C-terminal serine residues by glycogen synthase kinase-3 (GSK3α/β). GSK3 requires prior phosphorylation of a priming site (typically by casein kinase 1 or PKA) before phosphorylating the principal regulatory sites on GYS (Ser641, Ser645 in GYS1, using residue numbering from human muscle glycogen synthase). Insulin activates glycogen synthesis by a dual mechanism: (1) PI3K → Akt → GSK3 Ser9/Ser21 phosphorylation → GSK3 inhibition → GYS dephosphorylation → glycogen synthase activation; (2) protein phosphatase 1 (PP1), activated by insulin signalling via PTG (protein targeting to glycogen), directly dephosphorylates GYS at multiple sites simultaneously. The opposing regulation of phosphorylase (activated by phosphorylation/AMP) and glycogen synthase (inhibited by phosphorylation) ensures that glycogen synthesis and degradation are reciprocally controlled and do not operate in futile-cycle fashion under most physiological conditions.

AMPK Cross-Talk with Glycogen Metabolism

AMPK plays a nuanced and context-dependent role in glycogen metabolism. On the synthetic side, AMPK phosphorylates GYS1 directly at Ser7 (AMPK site), contributing to glycogen synthase inhibition during energy deficit — a logical adaptation since glycogen synthesis consumes UDP-glucose and ATP. AMPK also phosphorylates and activates PFK-2 (6-phosphofructo-2-kinase) to produce fructose-2,6- bisphosphate, a potent allosteric activator of PFK-1 that drives glycolytic flux. On the glycogenolytic side, AMPK does not directly phosphorylate phosphorylase or PhK, but the rise in AMP that activates AMPK simultaneously activates phosphorylase b allosterically (since both enzymes share AMP as activating ligand — AMP binding to AMPK γ subunit CBS domains activates AMPK; the same AMP pool activates GP-b at its allosteric site). This creates a coherent metabolic response where a single metabolic signal (falling AMP:ATP) simultaneously accelerates glycogen breakdown and activates AMPK-mediated adaptations. After exercise, when AMPK activity falls and insulin rises, AMPK phosphorylation of GYS1 Ser7 is removed and GYS is reactivated — the window for post-exercise glycogen supercompensation is mechanistically downstream of AMPK dephosphorylation.

Practical Takeaway: Glycaemia and Athletic Recovery

Spirulina's well-characterised AMPK activation (demonstrated in hepatic, muscle, and endothelial cell models) has two distinct glycogen-relevant consequences depending on metabolic context. In the post-absorptive or fasting state, AMPK activation in hepatocytes contributes to limiting hepatic glycogen synthesis and enhancing fatty acid oxidation, supporting fasting glycaemia without requiring excessive hepatic glycogenolysis — a mechanism relevant to spirulina's documented reductions in fasting blood glucose in type 2 diabetic subjects. In the exercise-recovery context, AMPK activation during training followed by its deactivation post-exercise (supported by spirulina's anti-inflammatory reduction of IL-6-driven AMPK prolongation) creates a favourable window for muscle glycogen resynthesis driven by GYS1 reactivation. The direct clinical data are limited: no published human trial has measured glycogen resynthesis rates after spirulina ingestion combined with carbohydrate loading. However, the mechanistic plausibility is solid, and several trials have demonstrated spirulina's reduction in fasting glucose (approximately 0.5–1.0 mmol/L in hyperglycaemic subjects over 8–12 weeks) and HOMA-IR, consistent with improved hepatic glycogen regulation via the AMPK–GSK3–GYS axis.